| NYHA | New York Heart Association Heart Disease에 대한 Functional Classification &nbs... |
|---|---|
| TRNB | Transient Respiratory distress of New Born |
| TTNB | Transient Tachypnea of New Born |
| ANDA | Abbreviated New Drug Application |
| IND | indomethacin; industrial medicine; investigational new drug |
| new yellow enzyme | The d-amino-acid oxidase found in yeast, a flavoenzyme, which contains FAD as coenzyme instead of FMN as does NADPH dehydrogenase; so-called to distinguish it from Warburg's old yellow enzyme. Compare: amino acid oxidases. (05 Mar 2000) |
|---|---|
| New York Heart Association classification | A functional classification to assess cardiovascular disability. Class I: patients with cardiac disease without limitation of physical activity. Ordinary activity does not cause symptoms. Class II: patients with cardiac disease with slight limitation of activity; comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea or angina. Class III: patients with cardiac disease producing marked limitation of activity: comfortable at rest. Less than ordinary physical activity causes symptoms. Class IV: patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms may be present even at rest. (05 Mar 2000) |
| new zealand | A group of islands in the South Pacific Ocean. New Zealand flax. <botany> A myrtaceous shrub (Leptospermum scoparium) of new Zealand and Australia, the leaves of which are used as a substitute for tea. Source: Websters Dictionary (01 Mar 1998) |
| New Zealand mice | Inbred strains of mice, either black (NZB) or white (NZW), unique among strains used in experimental immunology because of their proclivity to spontaneous immunologic abnormalities and disorders including systemic lupus erythematosus similar to that found in humans. (05 Mar 2000) |
| investigational new drug | Status given an experimental drug after the FDA approves an application for testing it in people. (09 Oct 1997) |
| investigational new drug application | An application that must be submitted to a regulatory agency (the FDA in the united states) before a drug can be studied in humans. This application includes results of previous experiments; how, where, and by whom the new studies will be conducted; the chemical structure of the compound; how it is thought to work in the body; any toxic effects found in animal studies; and how the compound is manufactured. (12 Dec 1998) |
| activation energy | <chemistry> The amount of energy (expressed in joules) that is needed to convert all the molecules in one mole of a reacting substance from a ground state to the transition state. (06 May 1997) |
| binding energy | <chemistry, radiobiology> The binding energy of a nucleus is the minimum energy required to dissociate it into its component neutrons and protons. Neutron or proton binding energies are those required to remove a neutron or proton, respectively, from a nucleus. Electron binding energy is that required to remove an electron from an atom or a molecule. (16 Dec 1997) |
| bioelectric energy sources | Implantable devices which convert biological energy (chemical energy of the metabolism of continuously regenerating body fluids or mechanical energy of periodic movements) to electrical energy. The sources include biogalvanic cells, biofuel cells, and ionic concentration cells. (12 Dec 1998) |
| biomass energy | See Bioenergy. (05 Dec 1998) |
| bond dissociation energy | This is the energy needed to break the bonds between two linked atoms. (09 Oct 1997) |
| bond energy | The energy needed to break a molecular bond. (09 Oct 1997) |
| radiant energy | Energy contained in light rays or any other form of radiation. (05 Mar 2000) |
| radiography, dual-energy scanned projection | A method of producing a high-quality scan by digitizing and subtracting the images produced by high- and low-energy X-rays. (12 Dec 1998) |
| radiotherapy, high-energy | Radiotherapy using high-energy (megavolt or higher) ionizing radiation. Types of radiation include gamma rays, produced by a radioisotope within a teletherapy unit; X-rays, electrons, protons, alpha particles (helium ions) and heavy charged ions, produced by particle acceleration; and neutrons and pi-mesons (pions), produced as secondary particles following bombardment of a target with a primary particle. (12 Dec 1998) |